UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction

Benzinga14:27

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Benzinga02:18

Needham Downgrades Biogen on Slow Growth of Alzheimer's Drug

Yahoo Finance00:30

Biogen on Track for Lowest Close Since March 2013 -- Data Talk

Dow JonesNov 18 23:54

This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

BenzingaNov 18 23:11

Express News | Samsung Bioepis and Biogen Receive European Commission (Ec) Approval for Aflibercept Biosimilar, Opuviz™

BreakingsNov 18 20:00